Idarubicin: Clinical Trials

247 trials of Idarubicin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

119 completed, 50 unknown, 33 recruiting, 17 terminated. 127 Phase 2, 67 Phase 3, 63 Phase 1, 18 Phase 4, 10 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2127Completed 62, Recruiting 20, Unknown 20, Terminated 10, Active not recruiting 8, Withdrawn 5, Not yet recruiting 2
Phase 367Completed 29, Unknown 21, Recruiting 7, Active not recruiting 4, Terminated 4, Not yet recruiting 2
Phase 163Completed 38, Withdrawn 6, Active not recruiting 5, Recruiting 5, Terminated 5, Unknown 3, Not yet recruiting 1
Phase 418Unknown 9, Completed 7, Recruiting 2
Not applicable10Unknown 6, Recruiting 3, Completed 1
Early Phase 12Completed 1, Recruiting 1

Follow Idarubicin: new trials by email Literature Review of Idarubicin trials Research Report on Idarubicin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center302026-11-302026-11-02
VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML
Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult
Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China3002026-04-302026-03-25
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF - AML (Acute Myeloid Leukemia)
Phase 2RecruitingBeijing 302 Hospital482026-04-152026-04-07
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
Mitoxantrone Hydrochloride Liposome, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML)
Phase 3Not yet recruitingThe First Affiliated Hospital of Soochow University2042026-03-102026-03-20
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Bleximenib, Cytarabine, Daunorubicin or Idarubicin - Acute Myeloid Leukemia
Phase 3RecruitingStichting Hemato-Oncologie voor Volwassenen Nederland8752026-03-012026-11-06
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 2RecruitingOHSU Knight Cancer Institute1022025-12-122026-10-20
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C) - Acute Myeloid Leukemia, Pediatric AML
Early Phase 1RecruitingBaylor College of Medicine362025-10-222026-08-24
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia
Phase 2RecruitingFred Hutchinson Cancer Center202025-09-262026-07-20
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Phase 1 / Phase 2RecruitingFred Hutchinson Cancer Center362025-09-232026-05-15
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Daunorubicin/Idarubicin, Cytarabine, Azacitidine - AML, Adult
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China2282025-08-312026-10-26
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). - AML (Acute Myelogenous Leukemia), Down Syndrome (DS)
Phase 3RecruitingFederal Research Institute of Pediatric Hematology, Oncology and Immunology1002025-07-242025-11-20
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
daunorubicin, Venetoclax, cytarabine - AML
Phase 2Active not recruitingInstitute of Hematology & Blood Diseases Hospital, China412025-01-212026-05-13
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
cytarabine, daunorubicin, idarubicin - AML, RUNX1-RUNX1T1 Fusion Protein Expression
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China2842025-01-102026-08-07
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Quizartinib, Placebo, Chemotherapy - Leukemia
Phase 3Active not recruitingDaiichi Sankyo7002024-11-192026-07-02
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
sonrotoclax, idarubicin/daunorubicin, Cytarabine - Acute Myeloid Leukemia
Phase 2Active not recruitingShanghai Jiao Tong University School of Medicine472024-10-302026-04-30
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Chidamide, Venetoclax, azacitidine - Acute Myeloid Leukemia
Phase 2RecruitingGuangdong Provincial People's Hospital2402024-08-212025-11-17
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab - Lung Cancer, Surgery
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University902024-07-012024-07-09
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab - Hepatic Cancer, Surgery
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University902024-07-012024-07-09
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab - Liver Cancer, Antibody
Phase 2RecruitingSecond Affiliated Hospital of Guangzhou Medical University902024-06-102024-07-01
MRD-positive AML Clinical Study
Ivosidenib, Gilteritinib, Venetoclax - AML, Adult
Not applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, China5372024-05-112026-08-10

Showing 20 of 247. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (151)  ·  Leukemia (67)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (29)  ·  Leukemia, Monocytic, Acute (26)  ·  Leukemia, Myelomonocytic, Acute (26)  ·  Myelodysplastic Syndromes (25)  ·  Leukemia, Erythroblastic, Acute (23)  ·  Congenital Abnormalities (22)  ·  Leukemia, Megakaryoblastic, Acute (22)  ·  Leukemia, Promyelocytic, Acute (13)  ·  Anemia, Refractory, with Excess of Blasts (12)  ·  Leukemia, Myelomonocytic, Chronic (12)  ·  Recurrence (10)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (8)  ·  Myeloproliferative Disorders (8)

Sponsors

M.D. Anderson Cancer Center (23)  ·  European Organisation for Research and Treatment of Cancer - EORTC (12)  ·  National Cancer Institute (NCI) (11)  ·  PETHEMA Foundation (11)  ·  Fred Hutchinson Cancer Center (9)  ·  Institute of Hematology & Blood Diseases Hospital, China (8)  ·  Children's Oncology Group (7)  ·  St. Jude Children's Research Hospital (6)  ·  Goethe University (5)  ·  Massachusetts General Hospital (5)  ·  Nanfang Hospital, Southern Medical University (5)  ·  University of Ulm (5)  ·  Arog Pharmaceuticals, Inc. (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Second Affiliated Hospital of Guangzhou Medical University (4)

Countries

United States (113)  ·  Germany (45)  ·  China (39)  ·  France (35)  ·  Italy (26)  ·  Spain (24)  ·  Belgium (18)  ·  United Kingdom (18)  ·  Canada (17)  ·  Netherlands (17)  ·  Australia (15)  ·  Austria (15)  ·  South Korea (13)  ·  Switzerland (11)  ·  Poland (10)

Top investigators

Farhad Ravandi-Kashani, MD (4)  ·  Zhenfeng Zhang, MD, PhD (4)  ·  Dieter Hoelzer, MD,PhD (3)  ·  Sergio Amadori, MD (3)  ·  Theo De Witte, MD, PhD (3)  ·  Alan K. Burnett, MD, FRCP (2)  ·  Amir Fathi, MD (2)  ·  Anthony S. Stein, MD (2)  ·  Franco Mandelli, MD (2)  ·  Guillermo Garcia-Manero (2)  ·  Hiroto Inaba, MD, PhD (2)  ·  Jorge Cortes (2)

Results publications

PMID 29702001, PMID 19144982, PMID 19602710, PMID 21343560, PMID 22442346, PMID 22493293, PMID 22512017, PMID 22965967, PMID 23024237, PMID 27561722, PMID 28751559, PMID 29427728, PMID 36892565, PMID 42477805, PMID 10499612, PMID 11426549, PMID 11468154, PMID 11981766, PMID 12049862, PMID 12091661, PMID 12540794, PMID 12627513, PMID 15087948, PMID 15154634, PMID 15339678, PMID 15761020, PMID 16136166, PMID 16197446, PMID 16333838, PMID 16932345, PMID 17315155, PMID 17339189, PMID 18039957, PMID 18083847, PMID 18182574, PMID 18286501, PMID 18398750, PMID 18648353, PMID 18802149, PMID 19059939, PMID 19242495, PMID 19291085, PMID 19304957, PMID 19688832, PMID 19805689, PMID 19826132, PMID 20038732, PMID 20056794, PMID 20393132, PMID 20413658

NIH funding

2015 (3), 2017 (3), P30CA015704 (3), P30CA016672 (3), U10CA098543 (3), 2008 (2), 2018 (2), 2023 (2), N01CM62202 (2), P30CA033572 (2), U10CA032102 (2), 2004 (1), 2014 (1), 2016 (1), 2025 (1)